LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SU11274 | 10 | uM | LJP5 | 3 | J07 | 72 | hr | 1401 | 1488 | 4545 | 0.3273 | 0.0359 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 1 | H12 | 72 | hr | 1401 | 1883 | 4139 | 0.4549 | 0.2081 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 2 | H12 | 72 | hr | 1401 | 1782 | 4095 | 0.4351 | 0.1680 |
| SK-BR-3 | Canertinib | 0.04 | uM | LJP6 | 3 | H12 | 72 | hr | 1401 | 1990 | 4272 | 0.4658 | 0.2436 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 1 | H11 | 72 | hr | 1401 | 1601 | 4139 | 0.3868 | 0.0889 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 2 | H11 | 72 | hr | 1401 | 1749 | 4095 | 0.4271 | 0.1539 |
| SK-BR-3 | Canertinib | 0.12 | uM | LJP6 | 3 | H11 | 72 | hr | 1401 | 1713 | 4272 | 0.4010 | 0.1329 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 1 | H10 | 72 | hr | 1401 | 1613 | 4139 | 0.3897 | 0.0941 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 2 | H10 | 72 | hr | 1401 | 1738 | 4095 | 0.4244 | 0.1492 |
| SK-BR-3 | Canertinib | 0.37 | uM | LJP6 | 3 | H10 | 72 | hr | 1401 | 1474 | 4272 | 0.3450 | 0.0319 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 1 | H09 | 72 | hr | 1401 | 1542 | 4139 | 0.3726 | 0.0630 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 2 | H09 | 72 | hr | 1401 | 1386 | 4095 | 0.3384 | -0.0072 |
| SK-BR-3 | Canertinib | 1.11 | uM | LJP6 | 3 | H09 | 72 | hr | 1401 | 1567 | 4272 | 0.3668 | 0.0719 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 1 | H08 | 72 | hr | 1401 | 1353 | 4139 | 0.3269 | -0.0223 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 2 | H08 | 72 | hr | 1401 | 1369 | 4095 | 0.3343 | -0.0151 |
| SK-BR-3 | Canertinib | 3.33 | uM | LJP6 | 3 | H08 | 72 | hr | 1401 | 1464 | 4272 | 0.3427 | 0.0275 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 1 | H07 | 72 | hr | 1401 | 1000 | 4139 | 0.2416 | -0.1943 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 2 | H07 | 72 | hr | 1401 | 1052 | 4095 | 0.2569 | -0.1693 |
| SK-BR-3 | Canertinib | 10 | uM | LJP6 | 3 | H07 | 72 | hr | 1401 | 1230 | 4272 | 0.2879 | -0.0780 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 1 | E18 | 72 | hr | 1401 | 4033 | 3978 | 1.0137 | 1.0181 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 2 | E18 | 72 | hr | 1401 | 4433 | 4213 | 1.0521 | 1.0651 |
| SK-BR-3 | NVP-AEW541 | 0.04 | uM | LJP5 | 3 | E18 | 72 | hr | 1401 | 4018 | 4545 | 0.8839 | 0.8597 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 1 | E17 | 72 | hr | 1401 | 4005 | 3978 | 1.0066 | 1.0088 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 2 | E17 | 72 | hr | 1401 | 4127 | 4213 | 0.9795 | 0.9741 |
| SK-BR-3 | NVP-AEW541 | 0.12 | uM | LJP5 | 3 | E17 | 72 | hr | 1401 | 4028 | 4545 | 0.8861 | 0.8625 |